State Food and Drug Administration Grants Approval to Sihuan Pharmaceutical for Clinical Trial of Innovative Drug -- Pinoxacin Hyd... (therapeutic areas in China . Chi ...)

HOME >> MEDICINE >> TECHNOLOGY

State Food and Drug Administration Grants Approval to Sihuan Pharmaceutical for Clinical Trial of Innovative Drug -- Pinoxacin Hydrochloride

Date:2/22/2013

therapeutic areas in China. China has an overall diabetes incidence rate of 9.7%, with the number of patients exceeding 100 million, making China the country with the largest number of diabetics in the world. Diabetes has also become the world's third largest therapeutic area after CCV diseases and tumor diseases, and therefore exhibits promising prospects.

Dr. Che Fengsheng, Chairman and CEO of Sihuan Pharmaceutical, said, "Further to obtaining clinical approval for Benapenum, a class of new drug, in January, the Company has again successfully obtained clinical approval for another new drug. This has proven the Company's strengthened research and development capabilities and that its continuous investment has started to bear fruit. We believe Pinoxacin Hydrochloride will provide physicians and patients with better treatment options after its launch, and will mark an important milestone for Sihuan Pharmaceutical as it enters into another major therapeutic area. This will enable the Company to further consolidate its diversified product lines while driving its sustainable growth."

About Sihuan Pharmaceutical Holdings Group Ltd.

Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. is a leading pharmaceutical company and the largest cardio-cerebral vascular drug franchise in China's prescription drug market by market share. The success of the Group can be attributed to its differentiated and proven sales and marketing model, diversified portfolio of market leading drugs, extensive nationwide distribution network, and strong research and development capabilities. Sihuan Pharmaceutical major products such as Kelinao, Anjieli, Chuanqing, Qu'Ao, GM1 and Oudimei are widely used in the treatment of various cardio-cerebral vascular diseases.

SOURCE Sihuan Pharmaceutical Holdings Group Ltd.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. U.S. FDA Grants Priority Review to Bayers Radium Ra 223 Dichloride NDA for Castration-Resistant Prostate Cancer with Bone Metastases
2. TorkLaw Responds to FDA Warning Letter to St. Jude Medical Regarding Defective Heart Device; Now Representing Patients in 15 States
3. Fox News Medical Contributor Explains Study of Side Effects from Prostate-Cancer Treatments
4. United States Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
5. Statement from Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on the Front Page New York Times Story Regarding the Pre-emptive Strikes of Amgen/Genentech to Restrict Access to Affordable and Safe Biosimilars
6. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
7. Oncologists in the United States and Europe Indicate that Novel Chemotherapies Hold the Most Near-Term Promise for Improving Outcomes in Soft Tissue Sarcoma
8. Virtual Ports Receives Patent Approvals in the United States and Japan
9. Amgen Backs States Efforts To Enact Biosimilar Legislation That Allows For Substitution And Supports Patient Safety
10. Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory
11. Medbox, Inc. Sees Opportunity in Several New States

Post Your Comments:

(Date:5/23/2013)... -- Echo Pharma Acquisition Limited ("Royalty Pharma") announced today that ... from 90 percent to 50 percent of Maximum Elan ... the terms of the Revised Offer Document issued today, ... the terms of the Increased Offer, Royalty Pharma is ... for $12.50 per share in cash. The Increased Offer ...

(Date:5/23/2013)... , May 23, 2013 BioLife Solutions , ... proprietary clinical grade hypothermic storage and ... contract aseptic media manufacturer , today announced its ... Regenerative Medicine Congress 2013 this week in ... ) Dr. Aby J. Mathew, BioLife,s Senior ...

(Date:5/23/2013)... and PARIS , May ... ), a leading developer and manufacturer of precision guided ... of coronary and peripheral vascular disease, today announced preliminary ... asodilator I ndependent S tenosis E ... clinical trial session at EuroPCR 2013. These prospective results ...

Breaking Medicine Technology:Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9 Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 2 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 3 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 4 Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013 5

[0] Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share [0] BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress [0] Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013

... A leader in healthcare, Henry Ford Health System will ... representing a "breakthrough" designed to improve treatment outcomes and ... admissions due to poor medication management by patients. ... programmable timers with Rexam prescription vials, which give audio ...

... BIOD ) today announced that it has entered into ... of its common stock and warrants to purchase 2,398,200 shares ... being sold as units, with each unit consisting of one ... share of common stock. The investors have ...

Cached Medicine Technology:Pharmacovigilance Breakthrough: Henry Ford Health System Partners with Rexam and Med Time Technology to Remind Patients to Take Prescription Medication "As Prescribed" to reduce $300 Billion National Healthcare Problem 2 Biodel to Raise $9.4 Million Through Registered Direct Offering 2 Biodel to Raise $9.4 Million Through Registered Direct Offering 3

Pharmacovigilance Breakthrough: Henry Ford Health System Partners with Rexam and Med Time Technology to Remind Patients to Take Prescription Medication "As Prescribed" to reduce $300 Billion National Healthcare Problem Biodel to Raise $9.4 Million Through Registered Direct Offering

(Date:5/23/2013)... have shown that an immune regulatory molecule called IL-21 ... viral infections. , The results are published in the ... how IL-21 could be important in the development of ... PhD, the first author of the paper. The senior ... Vaccine Center and a Georgia Research Alliance Eminent Scholar. ...

(Date:5/23/2013)... Netsmart today announced it is ranked ... information technology (HIT) providers for 2013. , The HCI 100 ... Healthcare Informatics magazine. Netsmart’s ranking of #49 is up ... growth is largely due to our commitment to helping organizations ... where resources are scarce, the demand for care is unprecedented ...

(Date:5/23/2013)... patients over the past two decades have found ... of new therapies, overall mortality has decreased and ... of severe abnormal heart rhythms, has declined. ... today, with these significant improvements, one-third of patients ... diagnosed with advanced disease. Heart failure is increasingly ...

(Date:5/23/2013)... (PRWEB) May 23, 2013 Elegance for a woman ... her flair, her taste, her intrigue can often be found in ... gateway to a woman's soul is through her eyes. It ... who she is! That is why the elegance of a woman ... . , Women today, more than any other time, utilize eyewear ...

(Date:5/23/2013)... 2013 A new report ... Medicaid program could save $2.1 billion without reducing access ... report shows that Florida and other state Medicaid programs ... and employers rely on to curb wasteful pharmacy spending. ... pharmacy at MedicaidPharmacySavings.com . , “The easiest way ...

Breaking Medicine News(10 mins):Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2 Health News:Netsmart Named to Healthcare Informatics Top 100 List 2 Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 2 Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 3 Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2 Health News:PCMA: Upgrading Medicaid Drug Benefits Could Save Florida $2.1 Billion 2

[0] Vaccine blackjack: IL-21 critical to fight against viral infections [0] Netsmart Named to Healthcare Informatics Top 100 List [0] Death rates decline for advanced heart failure patients, but outcomes are still not ideal [0] Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc.[0] PCMA: Upgrading Medicaid Drug Benefits Could Save Florida $2.1 Billion

... Eating Tips to Stay Balanced Through the ... ... Registered dietitian, celebrity,chef, and New York Times best-selling author Ellie Krieger, ... the benefits of,digestive health. Yo-Plus contains live and active probiotic cultures,specifically ...

... N.C., Nov. 5 Cornerstone Therapeutics,Inc. (Nasdaq ... on,developing and commercializing prescription medications for respiratory,disorders, ... of the recently,completed merger between Cornerstone BioPharma ... Collard, 42, president and chief executive,officer and ...

... 5 CardiacAssist, Inc. announced that,it reached a new high ... least one TandemHeart case during the third quarter of 2008.,In ... on,year growth in case activity with a leap of 64 ... and 497 %. Through nine months of 2008,CardiacAssist has also ...

... Corporate Highlights:, -- Net service revenues increased 84% to $58.7 ... to $48.6 million -- Net income increased 149% to $4.7 ... share on 49% more shares -- Completed acquisition of Patient ... 200 Best Small Companies List, Almost Family, Inc. (Nasdaq: ...

... to ... 9-hour flights, HOBOKEN, N.J., Nov. 5 ... pine bark,extract from the French maritime pine tree, reduces jetlag in passengers ... and a,scoring system, showed Pycnogenol(R) lowered symptoms of jetlag such as,fatigue, headaches, ...

... Nov. 5 CuraGen Corporation,(Nasdaq: CRGN ), a ... Timothy M. Shannon, President and Chief,Executive Officer, will present ... Investment Conference on Wednesday, November 12, 2008, at,3:15 p.m. ... New York Palace,Hotel in New York, NY., Access ...

Healthy Eating Expert Ellie Krieger Joins Yoplait(R) Yo-Plus(TM) to Raise Awareness of Digestive Health Cornerstone Therapeutics Announces New Board of Directors CardiacAssist, Inc. Announces Record Breaking Site Activity and Financial Results Almost Family Reports Third Quarter 2008 Results Study Shows Pine Bark Reduces Jetlag CuraGen to Present at the Rodman & Renshaw Annual Global Investment Conference

Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With Tubular Base....

Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....

... an independent laboratory to ... of Federal Standard 209E. ... confort, reduces fatique and ... meets Class 100 particle ...

Medicine Products:

4V62 4V42-R 4V41-R Class 100 Chair